JPRN-UMIN000007307已完成2 期
The randomized phaseII study about the skin hazard mitigation in the Erlotinib + oral steroid agent combined therapy and Erlotinib to non-small cell lung cancer patients - The randomized phaseII study about the skin hazard mitigation in the Erlotinib + oral steroid agent combined therapy and Erlotinib to non-small cell lung cancer patients
Respiratory Medicine, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine.0 个研究点目标入组 80 人开始时间: 2012年2月16日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. History of severe drug allergy 2.Prior treatment with drugs (Gefitinib or Cetuximab)which act on an EGFR system. 3.The patient by whom revelation of a critical adverse event is expected with a prednisolone tablet 4. Pregnant or breast-feeding females 5.Patient of the past of an active interstitial lung obstacle or a merger 6. Uncontrollable infectious disease 7. Uncontrollable peptic ulcer 8. Glaucomatous patient 9. Patient of serious illness skin disease 10. The patient who has critical complications. (Uncontrollable cardiac disease, liver cirrhosis, continuous watery diarrhea) 11. The patient in whom oral ingestion is impossible. 12. Decision of ineligibility by a physician
研究者
相似试验
进行中（未招募）
1 期
A Study Evaluating Venetoclax in Combination with Azacitidine Compared with Azacitidine Alone in Subjects with Previously Untreated Higher-Risk Myelodysplastic Syndromes (MDS)EUCTR2016-001657-41-DEAbbVie Deutschland GmbH & Co. KG90
进行中（未招募）
1 期
A Study Evaluating Venetoclax in Combination with Azacitidine Compared with Azacitidine Alone in Subjects with Previously Untreated Higher-Risk Myelodysplastic Syndromes (MDS)EUCTR2016-001657-41-GBAbbVie Deutschland GmbH & Co. KG90
进行中（未招募）
1 期
Evaluating Avelumab in combination with Cetuximab in Head and neck cancer (EACH)recurrent/metastatic head and neck squamous cell cancerMedDRA version: 20.0 Level: PT Classification code 10067821 Term: Head and neck cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: PT Classification code 10060121 Term: Squamous cell carcinoma of head and neck System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-003592-64-GBniversity College London130
进行中（未招募）
1 期
Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and BevacizumabColorectal CancerCTIS2023-505110-14-00AbbVie Deutschland GmbH & Co. KG206
进行中（未招募）
不适用
A randomized Phase IIa trial evaluating the safety and efficacy of a new centrally acting analgesic in subjects with pain due to diabetic polyneuropathypainful diabetic polyneuropathyMedDRA version: 9.1Level: LLTClassification code 10012685Term: Diabetic polyneuropathyEUCTR2008-004794-18-DEGrünenthal GmbH108